


Abiraterone COU-AA-302

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



Abiraterone COU-AA-302

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers  
Therapeutic Indication: Treatment of mCRPC in adult men who are asymptomatic or mildly symptomatic after failure of ADT in whom ChT is not yet clinically indicated  
Experimental Arm: Abiraterone + Prednisone  
Control Arm: Placebo–prednisone

